THE MEDICAL COLLEGE OF WISCONSIN, INC.

The CAST regimen (post-transplant cyclophosphamide, abatacept, and tacrolimus) after haploidentical HSCT shows promising results in preventing GVHD, with reduced relapse rates and improved survival compared to standard regimens. This could address disparities in donor availability, especially for minority groups.